These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 7804370)

  • 1. Subcutaneous recombinant interleukin-2 and alpha-interferon in patients with advanced renal cell carcinoma: results of a multicenter Phase II Study.
    Atzpodien J; Kirchner H; de Mulder P; Bodenstein H; Oliver T; Palmer PA; Franks CR; Poliwoda H
    Cancer Biother; 1993; 8(4):289-300. PubMed ID: 7804370
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiinstitutional home-therapy trial of recombinant human interleukin-2 and interferon alfa-2 in progressive metastatic renal cell carcinoma.
    Atzpodien J; Lopez Hänninen E; Kirchner H; Bodenstein H; Pfreundschuh M; Rebmann U; Metzner B; Illiger HJ; Jakse G; Niesel T
    J Clin Oncol; 1995 Feb; 13(2):497-501. PubMed ID: 7844611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-2 based home therapy of metastatic renal cell carcinoma: risks and benefits in 215 consecutive single institution patients.
    Lopez Hänninen E; Kirchner H; Atzpodien J
    J Urol; 1996 Jan; 155(1):19-25. PubMed ID: 7490829
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined subcutaneous recombinant alpha-interferon and interleukin-2 in metastatic renal cell cancer: results of the Multicentre All Ireland Immunotherapy Study Group.
    Rogers E; Bredin H; Butler M; Corcoran M; Egan E; Fennelly J; Grainger R; Aleer SM; Dermott TM; Mullins G; Tanner A; Twomey A; Thornhill J
    Eur Urol; 2000 Mar; 37(3):261-6. PubMed ID: 10720849
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Interleukin 2 based ambulatory therapy of metastatic renal cell carcinoma].
    Atzpodien J; Kirchner H; Poliwoda H
    Med Klin (Munich); 1996 Apr; 91 Suppl 3():38-43. PubMed ID: 8692118
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Daily alternating administration of high-dose alpha-2b-interferon and interleukin-2 bolus infusion in metastatic renal cell cancer. A phase II study.
    Bergmann L; Fenchel K; Weidmann E; Enzinger HM; Jahn B; Jonas D; Mitrou PS
    Cancer; 1993 Sep; 72(5):1733-42. PubMed ID: 8348502
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of metastatic renal cell cancer patients with recombinant subcutaneous human interleukin-2 and interferon-alpha.
    Atzpodien J; Körfer A; Palmer PA; Franks CR; Poliwoda H; Kirchner H
    Ann Oncol; 1990 Sep; 1(5):377-8. PubMed ID: 2261378
    [TBL] [Abstract][Full Text] [Related]  

  • 8. alpha-Interferon and interleukin-2 in renal cell carcinoma: studies in nonhospitalized patients.
    Atzpodien J; Poliwoda H; Kirchner H
    Semin Oncol; 1991 Oct; 18(5 Suppl 7):108-12. PubMed ID: 1948123
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interleukin-2-based therapy for metastatic renal cell cancer: the Cytokine Working Group experience, 1989-1997.
    Dutcher JP; Atkins M; Fisher R; Weiss G; Margolin K; Aronson F; Sosman J; Lotze M; Gordon M; Logan T; Mier J
    Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S73-8. PubMed ID: 9457399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I and II trials of subcutaneously administered rIL-2, interferon alfa-2a, and fluorouracil in patients with metastatic renal carcinoma.
    Olencki T; Peereboom D; Wood L; Budd GT; Novick A; Finke J; McLain D; Elson P; Bukowski RM
    J Cancer Res Clin Oncol; 2001 May; 127(5):319-24. PubMed ID: 11355147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Subcutaneous low-dose recombinant interleukin 2 and alpha-interferon in patients with metastatic renal cell carcinoma.
    Ravaud A; Négrier S; Cany L; Merrouche Y; Le Guillou M; Blay JY; Clavel M; Gaston R; Oskam R; Philip T
    Br J Cancer; 1994 Jun; 69(6):1111-4. PubMed ID: 8198979
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subcutaneous interleukin-2 and interferon-alpha 2b in patients with metastatic renal cell cancer: the German outpatient experience.
    Kirchner H; Körfer A; Palmer PA; Evers P; De Riese W; Knüver-Hopf J; Hadam M; Goldman U; Franks CR; Poliwoda H
    Mol Biother; 1990 Sep; 2(3):145-54. PubMed ID: 2222898
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical study on recombinant human interleukin-2 (Proleukin) in the treatment of metastatic renal cell carcinoma].
    Sheng XN; Li JL; Guo J; Zhao XH; Zhu J; Chu DT
    Zhonghua Zhong Liu Za Zhi; 2008 Feb; 30(2):129-33. PubMed ID: 18646697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-2 and interferon-alpha-2a outpatient therapy for metastatic renal cell carcinoma.
    Lipton A; Harvey H; Givant E; Hopper K; Lawler J; Matthews Y; Hirsh M; Zeffren J
    J Immunother Emphasis Tumor Immunol; 1993 Feb; 13(2):122-9. PubMed ID: 8318497
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Subcutaneous interleukin-2 and interferon alpha in the treatment of patients with metastatic renal cell carcinoma-Less efficacy compared with intravenous interleukin-2 and interferon alpha. Results of a multicenter Phase II trial from the Groupe Français d'Immunothérapie.
    Ravaud A; Delva R; Gomez F; Chevreau C; Douillard JY; Peny J; Coudert B; Négrier S;
    Cancer; 2002 Dec; 95(11):2324-30. PubMed ID: 12436438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II trial of interleukin-2 and interferon-alpha in patients with renal cell carcinoma: clinical results and immunologic correlates of response.
    Bukowski RM; Olencki T; Wang Q; Peereboom D; Budd GT; Elson P; Sandstrom K; Tuason L; Rayman P; Tubbs R; McLain D; Klein E; Novick A; Finke J
    J Immunother; 1997 Jul; 20(4):301-11. PubMed ID: 9220320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Biochemotherapy of advanced metastatic renal-cell carcinoma: results of the combination of interleukin-2, alpha-interferon, 5-fluorouracil, vinblastine, and 13-cis-retinoic acid.
    Atzpodien J; Kirchner H; Duensing S; Lopez Hänninen E; Franzke A; Buer J; Probst M; Anton P; Poliwoda H
    World J Urol; 1995; 13(3):174-7. PubMed ID: 7550391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hyperdynamic hemodynamics following high-dose interleukin 2-interferon alpha therapy in patients with metastatic renal cell carcinoma. Immunotherapy as a clinical sepsis model?].
    Finck-Seelen ; Lampert R; Brandt L
    Anaesthesist; 1996 Dec; 45(12):1171-8. PubMed ID: 9065251
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Continuous intravenous interleukin-2 infusion and subcutaneous interferon-alpha in metastatic renal cell carcinoma.
    Fosså SD; Aune H; Baggerud E; Granerud T; Heilo A; Theodorsen L
    Eur J Cancer; 1993; 29A(9):1313-5. PubMed ID: 8343275
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.